Sep 26, 2023 / 09:00AM GMT
Peter Keeling - Diaceutics PLC - Founder, CEO & Executive Director
Hello, everybody, and it's Peter Keeling here. I'm delighted to bring you our H1 results and walk through an update to the business. And we spent a little bit of time reflecting on the feedback that we've had over the last series of cycles of presentations and attempted to really improve and articulate the story as we tell it today. So hopefully, you'll see that in the slides. If you would move on to the next slides, please.
Next slide. So at the top of the meeting, a few kind of key notes. No doubt, we will come back to these in the Q&A and through the next section as we're talking about the financial reports. And we have undergone a CEO transition announced this morning, delighted to say that Ryan has stepped in to be CEO designate. And Ryan and I are really cofounders of this business. We've walked the journey of Diaceutics together over a long number of years.
And Ryan, in particular, has been a chief architect of key pillars of the business, the data, the lab network, the platform, both the logical choice and
Half Year 2023 Diaceutics PLC Earnings Call Transcript
Mar 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers